In many tumour types serumlactate dehydrogenase (LDH) levels proved to represent an indirect marker of tumour hypoxia, neo-angiogenesis and worse prognosis. As we previously reported LDH is an important predictive factor in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE). Sorafenib represents the therapeutic stronghold in advanced HCC patients. As a tyrosine kinase inhibitor (TKI) mainly directed against the angiogenetic pathway, the correlation of sorafenib administration with markers of hypoxia could be an important tool in patients management. Aim of our analysis was to evaluate the role of LDH pre-treatment levels and its variation during treatment in HCC patients receiving sorafenib.

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management / Faloppi, Luca; Scartozzi, Mario; Bianconi, Maristella; SVEGLIATI BARONI, Gianluca; Toniutto, Pierluigi; Giampieri, Riccardo; DEL PRETE, Michela; DE MINICIS, Samuele; Bitetto, Davide; Loretelli, Cristian; D' ANZEO, Marco; Benedetti, Antonio; Cascinu, Stefano. - In: BMC CANCER. - ISSN 1471-2407. - ELETTRONICO. - 14:1(2014), p. 110. [10.1186/1471-2407-14-110]

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management

FALOPPI, LUCA;BIANCONI, MARISTELLA;SVEGLIATI BARONI, Gianluca;GIAMPIERI, RICCARDO;DEL PRETE, MICHELA;DE MINICIS, SAMUELE;LORETELLI, CRISTIAN;D' ANZEO, MARCO;BENEDETTI, Antonio;CASCINU, Stefano
2014-01-01

Abstract

In many tumour types serumlactate dehydrogenase (LDH) levels proved to represent an indirect marker of tumour hypoxia, neo-angiogenesis and worse prognosis. As we previously reported LDH is an important predictive factor in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE). Sorafenib represents the therapeutic stronghold in advanced HCC patients. As a tyrosine kinase inhibitor (TKI) mainly directed against the angiogenetic pathway, the correlation of sorafenib administration with markers of hypoxia could be an important tool in patients management. Aim of our analysis was to evaluate the role of LDH pre-treatment levels and its variation during treatment in HCC patients receiving sorafenib.
2014
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/224984
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 35
  • Scopus 81
  • ???jsp.display-item.citation.isi??? 79
social impact